Business Context and Reporting Period
This Form 8-K Current Report was filed by Pieris Pharmaceuticals, Inc. (PIRS) on November 4, 2022. The filing discloses the entry into a material definitive agreement regarding an amendment to an existing Open Market Sale Agreement with Jefferies LLC.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, cash flow, or margins. The relevant financial data pertains to capital raising activities:
- Program Type: "At the market" (ATM) offering program.
- Previous Capacity (2021 ATM Program): $50.0 million aggregate gross sales proceeds.
- Amount Sold to Date (as of Nov 4, 2022): Approximately $33.6 million.
- New Aggregate Capacity (Post-Amendment): Up to $75.0 million.
- Remaining Capacity: Approximately $41.4 million (calculated as $75.0 million total capacity less $33.6 million previously sold).
Material Changes
On November 4, 2022, Pieris Pharmaceuticals entered into Amendment No. 1 to its Sales Agreement with Jefferies LLC. The material change is an increase in the aggregate offering amount available under the program:
- The aggregate offering price limit was increased from $50.0 million to $75.0 million.
- This increase is exclusive of shares previously sold under the 2021 ATM Program.
- All other material terms and conditions of the Sales Agreement remain unchanged.
Outlook, Risks, and Management Commentary
Management Commentary: The Company is not obligated to make any sales of shares under the Amended Sales Agreement. Sales will be made at the Company's discretion based on market conditions and instructions regarding price, time, or size limits.
Risks and Contingencies: The filing notes that sales will be made only if permitted by law and in accordance with the prospectus supplement. The report explicitly states it does not constitute an offer to sell securities in any jurisdiction where such an offer would be unlawful.
Investor Verification Checklist
- Verify the exact number of shares sold to date under the 2021 ATM Program to calculate the precise remaining share count available for sale.
- Review the full text of Exhibit 1.1 (Amendment No. 1) for any specific conditions or termination rights not detailed in the summary.
- Monitor future 10-Q or 10-K filings to track the actual utilization of the new $75.0 million capacity and the impact on share dilution.
- Confirm the current trading price of PIRS on the Nasdaq Capital Market to assess the potential dilution impact of future sales.